Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Irampanel Boehringer Ingelheim.

Valery Feigin1

  • 1University of Auckland, Department of Medicine, New Zealand. v.feigin@ctru.auckland.ac.nz

Current Opinion in Investigational Drugs (London, England : 2000)
|July 26, 2002
PubMed
Summary

Irampnel, an AMPA receptor antagonist, was investigated for stroke treatment. Development for stroke and other neurological disorders appears to have been discontinued by 2002.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Demographic Refinement and Atrial Fibrillation Type in Stroke Risk Stratification Beyond CHA2DS2 VASc.

Cerebrovascular diseases extra·2026
Same author

Clinical characteristics associated with ischaemic stroke and transient ischaemic attack among non-anticoagulated patients with atrial fibrillation.

The New Zealand medical journal·2026
Same author

Variation in the use of electrical cardioversion and catheter ablation for atrial fibrillation/flutter according to sex and ethnicity in Aotearoa New Zealand.

The New Zealand medical journal·2026
Same author

Mechanisms of ischaemic strokes and transient ischaemic attacks despite oral anticoagulation in patients with atrial fibrillation.

The New Zealand medical journal·2026
Same author

PERKS-International: A Randomized Controlled Trial Testing the Efficacy of an mHealth Application to Reduce Risk Factors for the Primary Prevention of Stroke.

Stroke·2026
Same author

Advancing brain health equity at the World Health Summit.

The Lancet. Neurology·2026

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Irampnel is an oxazole derivative and a non-competitive AMPA receptor antagonist.
  • It was under development by Boehringer Ingelheim for potential therapeutic applications.

Purpose of the Study:

  • To evaluate irampanel as a potential treatment for stroke.
  • Initial investigations also included epilepsy and pain management.

Main Methods:

  • Phase I/IIa clinical trials for stroke were initiated by July 2000.
  • Phase II trials were ongoing in April 2001.

Main Results:

  • By April 2002, irampanel was no longer listed on the company's research and development pipeline.
  • The current development status of irampanel could not be confirmed by a company spokesperson.

Conclusions:

  • Development of irampanel for stroke and other neurological disorders, including epilepsy and pain, was likely discontinued.
  • The compound's therapeutic potential remains uncertain due to the lack of confirmed development status.

Related Experiment Videos